Passage BIO (PASG) Common Equity (2019 - 2026)
Passage BIO (PASG) reported Common Equity of $4.46 million for Q2 2026, down 88.4% from $38.26 million a year earlier and down 62.1% from the prior quarter.
Passage BIO (PASG) Common Equity (2019 - 2026) Analysis & Trends
At the end of FY2025, Passage BIO posted Common Equity of $18.76 million, down 69.4% from FY2024.
- Common Equity has declined for four consecutive years, with a five-year compound annual growth rate of -42.7% (FY2020 to FY2025).
- By year, Common Equity came in at $61.26 million in FY2024 (-45.0%), $111.28 million in FY2023 (-44.7%), $201.37 million in FY2022 (-36.8%) and $318.66 million in FY2021 (+4.6%).
- The Q2 2026 figure ranks as the lowest quarterly Common Equity since Q4 2019.
- Year over year, Common Equity has now declined in each of the last 18 quarters, with an average decline of 61.3% over the last eight quarters.
- The high point for year-over-year Common Equity in five years was Q3 2021 (growth of 6.9%); the low point was Q2 2026 (a decline of 88.4%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $11.75 million (Q1 2026), $18.76 million (Q4 2025) and $31.12 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 40.27 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | -4.58 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 44.95 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 51.81 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 14.35 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 13.04 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 89.30 Bn |
| 10 | Passage BIO | 12.16 Mn | -111.84 Mn | - | 50,000.00 |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 50,000.00 |
| Jun 30, 2026 | 4.46 Mn |
| Mar 31, 2026 | 11.75 Mn |
| Dec 31, 2025 | 18.76 Mn |
| Sep 30, 2025 | 31.12 Mn |
| Jun 30, 2025 | 38.26 Mn |
| Mar 31, 2025 | 46.71 Mn |
| Dec 31, 2024 | 61.26 Mn |
| Sep 30, 2024 | 72.72 Mn |
| Jun 30, 2024 | 90.56 Mn |
| Mar 31, 2024 | 104.88 Mn |
| Dec 31, 2023 | 111.28 Mn |
| Sep 30, 2023 | 126.28 Mn |
| Jun 30, 2023 | 150.41 Mn |
| Mar 31, 2023 | 170.35 Mn |
| Dec 31, 2022 | 201.37 Mn |
| Sep 30, 2022 | 224.40 Mn |
| Jun 30, 2022 | 248.05 Mn |
| Mar 31, 2022 | 281.31 Mn |
| Dec 31, 2021 | 318.66 Mn |
Passage BIO Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=PASG&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "PASG", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=PASG&period=max&api_key=YOUR_API_KEY");
const data = await res.json();